Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.46 |
| ▸ | KIT | P10721 | 2/20 | 0.46 |
| ▸ | CKS1B | P61024 | 1/20 | 0.45 |
| ▸ | SKP1 | P63208 | 1/20 | 0.45 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.45 |
| ▸ | ACHE | P22303 | 2/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | GBA1 | P04062 | 2/20 | 0.41 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1775118 | 0.96 | KIT (0.48) | KITCKS1BSKP1SKP2ACHE | |
| SCHEMBL1775472 | 0.85 | PDE10A (0.41) | PDE10AKITCKS1BSKP1SKP2 | |
| SCHEMBL1776396 | 0.84 | RECQL (0.39) | MEN1KMT2A | |
| SCHEMBL12601535 | 0.81 | PDE10A (0.51) | PDE10AKITCKS1BSKP1SKP2 | |
| SCHEMBL1774258 | 0.79 | RECQL (0.41) | KITMEN1KMT2A | |
| SCHEMBL5850542 | 0.78 | KIT (0.54) | KITMEN1KMT2AGBA1 | |
| SCHEMBL1776248 | 0.78 | KIT (0.50) | PDE10AKITCKS1BSKP1SKP2 | |
| SCHEMBL12601536 | 0.76 | BACE1 (0.51) | PDE10AKITCKS1BSKP1SKP2 | |
| SCHEMBL1774703 | 0.76 | KIT (0.42) | KITGPR119GBA1GRIA1 | |
| SCHEMBL11963375 | 0.76 | CKS1B (0.55) | PDE10ACKS1BSKP1SKP2ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7943639-B2 | Such as 6-benzenesulfonyl-4-piperazin-1-yl-quinoline hydrochloride; for treatment of central nervous system and/or 5- HT6 receptor related disorders; for weight gain/loss | PROXIMAGEN LIMITED (GB) | 2011-05-17 | — | — | US | disclosed |
| EP-1897881-A2 | Compounds useful for the treatment of obesity, type II diabetes and CNS disorders | Biovitrum AB (publ) (SE) | 2008-03-12 | — | — | EP | disclosed |
| US-20040024210-A1 | New compounds | PROXIMAGEN NEUROSCIENCE PLC (GB) | 2004-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040024210-A1 | New compounds | SULT1E1, SULT2A1, SULT1A1 | PDE10A 1262/4885KIT 4787/4885CKS1B 2454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.